Elite Pharmaceuticals, Inc. (ELTP) Net margin 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) net profit margin by fiscal year — reported net income divided by reported revenue.
30.1%FY2026 · since FY2017: 39.5% → 30.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 30.1% | +35.3 pp |
| FY2025 | -5.1% | -40.6 pp |
| FY2024 | 35.5% | +25.1 pp |
| FY2023 | 10.4% | -17.2 pp |
| FY2022 | 27.6% | +7.5 pp |
| FY2021 | 20.0% | +32.5 pp |
| FY2020 | -12.5% | +110.2 pp |
| FY2019 | -122.6% | -73.4 pp |
| FY2018 | -49.2% | -88.8 pp |
| FY2017 | 39.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice